Dashboard
Manage Tickers

AGEN AGENUS INC

Nasdaq agenusbio.com


$ 4.36 $ 0.01 (0.23 %)    

Friday, 14-Nov-2025 15:54:09 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 4.34
$ 4.21
$ 4.34 x 400
$ 4.35 x 22
$ 4.21 - $ 4.44
$ 1.38 - $ 7.34
366,427
na
147.6M
$ 2.12
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-10-2025 09-30-2025 10-Q
2 08-11-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-17-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 03-14-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-09-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-08-2022 09-30-2022 10-Q
14 08-09-2022 06-30-2022 10-Q
15 05-10-2022 03-31-2022 10-Q
16 03-01-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-09-2021 06-30-2021 10-Q
19 05-07-2021 03-31-2021 10-Q
20 03-16-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-09-2019 06-30-2019 10-Q
27 05-10-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-07-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-10-2018 03-31-2018 10-Q
32 03-16-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-07-2017 06-30-2017 10-Q
35 05-04-2017 03-31-2017 10-Q
36 03-16-2017 12-31-2016 10-K
37 11-09-2016 09-30-2016 10-Q
38 08-04-2016 06-30-2016 10-Q
39 05-09-2016 03-31-2016 10-Q
40 03-15-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

agenus-q3-eps-194-misses-198-estimate-sales-30200m-miss-55713m-estimate
Agenus Q3 EPS $1.94 Misses $1.98 Estimate,...
11/10/2025 12:32:05

Agenus (NASDAQ:AGEN) reported quarterly earnings of $1.94 per share which missed the analyst consensus estimate of $1.98 by 2.0...

earnings-scheduled-for-november-10-2025
Earnings Scheduled For November 10, 2025
11/10/2025 11:12:02

insights-ahead-agenuss-quarterly-earnings
Insights Ahead: Agenus's Quarterly Earnings
11/07/2025 20:05:48

agenus-releases-new-data-from-its-botensilimab-and-balstilimab-combination-showing-durable-survival-benefits-across-multiple-late-stage-treatment-resistant-cancers-and-that-40-of-patients-with-very-limited-survival-expectation-are-alive-at-two-years
Agenus Releases New Data From Its botensil...
10/17/2025 12:10:31

Durable survival in heavily pretreated patients, including those who failed prior immunotherapy and with active liver metastase...

agenus-says-closing-of-deals-with-zydus-pharmaceuticals-shifted-to-q4-2025
Agenus Says Closing Of Deals With Zydus Ph...
09/23/2025 21:28:11

-SEC Filing

hc-wainwright--co-reiterates-buy-on-agenus-maintains-23-price-target
HC Wainwright & Co. Reiterates Buy on Agen...
09/10/2025 10:49:56

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.

agenus-says-investigational-combination-botbal-now-available-to-eligible-patients-with-refractory-mss-mcrc-under-frances-compassionate-access-framework
Agenus Says Investigational Combination BO...
09/09/2025 11:45:49

Agenus Inc. (NASDAQ:AGEN), a leader in immuno‑oncology, today announced its investigational combination botensilimab plus balst...

hc-wainwright--co-reiterates-buy-on-agenus-maintains-23-price-target
HC Wainwright & Co. Reiterates Buy on Agen...
08/28/2025 10:50:37

HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $23 price target.

agenus-to-host-aug-27-virtual-briefing-highlighting-cancer-drug-pipeline-and-phase-3-crc-study
Agenus to Host Aug. 27 Virtual Briefing Hi...
08/19/2025 11:33:51

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will host a virtua...

agenus-q2-eps-100-misses-058-estimate-sales-25700m-miss-49710m-estimate
Agenus Q2 EPS $(1.00) Misses $0.58 Estimat...
08/11/2025 11:39:38

Agenus (NASDAQ:AGEN) reported quarterly losses of $(1.00) per share which missed the analyst consensus estimate of $0.58 by 273...

Core News & Articles
Earnings Scheduled For August 11, 2025
08/11/2025 08:32:28

examining-the-future-agenuss-earnings-outlook
Examining the Future: Agenus's Earnings Ou...
08/08/2025 19:03:29

agenus-to-present-clinical-progress-across-botensilimab-and-balstilimab-immunotherapy-programs-at-esmo-congress-2025
Agenus To Present Clinical Progress Across...
07/25/2025 16:55:22

Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today announced that four abstracts highlighting clinical progress acro...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
07/07/2025 17:06:57

agenus-confirms-agreement-with-fda-on-design-of-global-battman-phase-3-trial
Agenus Confirms Agreement With FDA On Desi...
07/07/2025 12:59:17

Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the globa...

agenus-says-botbal-combination-achieves-2-yr-survival-rate-of-42-along-with-now-more-mature-21-month-median-os-in-expanded-cohort-of-123-patients-with-mss-mcrc-without-active-liver-metastases
Agenus Says BOT/BAL Combination Achieves 2...
07/07/2025 12:57:43

Agenus Inc. (NASDAQ:AGEN) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BA...

agenus-announces-research-collaboration-to-develop-predictive-biomarkers-of-response-to-clinical-stage-io-combination-botensilimab
Agenus Announces Research Collaboration To...
06/17/2025 11:31:42

Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients ...

agenus-enters-into-asset-purchase-agreement-with-zydus-pharmaceuticals-sells-manufacturing-operations-to-zydus-pharmaceuticals-for-up-to-125m
Agenus Enters Into Asset Purchase Agreemen...
06/04/2025 20:47:41

On June 3, 2025, Agenus Inc. (the "Company") and its wholly-owned subsidiary Agenus West, LLC ("Agenus West" an...

analyst-upgrades-agenus-as-zydus-deal-alleviates-cash-overhang
Analyst Upgrades Agenus As Zydus Deal Alle...
06/04/2025 18:38:22

Zydus acquires two Agenus biologics facilities in California for $75 million, expanding U.S. CDMO presence and securing rights ...

baird-maintains-neutral-on-agenus-raises-price-target-to-6
Baird Maintains Neutral on Agenus, Raises ...
06/04/2025 13:01:15

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:AGEN) with a Neutral and raises the price target from $4 to $6.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION